August 6, 2025Open Access

Cost-Effectiveness Analysis of the mRNA-1345 RSV Vaccine for Adults in the United States: Clinical and Economic Value

View Full Paper

Ask AI

Bookmark

Authors

KHKatherine A. HicksRTI Health Solutions ZXZiyi XiaoRTI Health Solutions KFKelly FustUniversity of the Holy Quran and Islamic Sciences

Discussion

Member takes

Implication

Cost-effectiveness analysis reveals mRNA-1345 vaccination could avert 280,000 hospitalizations in adults, indicating significant public health benefits.

Key Points

Vaccination with mRNA-1345 in high-risk adults aged 18-59 and seniors could avert over 280,000 hospitalizations.
The model estimates 19,000 deaths averted and 244,000 quality-adjusted life-years gained within five years.
Vaccination is projected to cost $23.2 billion but saves $10.8 billion in direct and $13.3 billion in indirect costs.
Overall, the strategy yields net savings of more than $810 million from a societal perspective, enhancing RSV prevention.

Cite This Study

Hicks et al. (2025) studied this question.

synapsesocial.com/papers/689a0f99e6551bb0af8d1677 https://doi.org/10.1101/2025.08.01.25332812

View Full Paper

Ask AI

Bookmark

Implication

Cost-effectiveness analysis reveals mRNA-1345 vaccination could avert 280,000 hospitalizations in adults, indicating significant public health benefits.

Cost-Effectiveness Analysis of the mRNA-1345 RSV Vaccine for Adults in the United States: Clinical and Economic Value

Discussion

Member takes

Implication

Key Points

Cite This Study

Cost-Effectiveness Analysis of the mRNA-1345 RSV Vaccine for Adults in the United States: Clinical and Economic Value

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider